Email Updates

Search form

You are here

AVAC in the News

  • Among all the CAR-T commotion you may have missed it: An FDA panel on Wednesday recommended Gilead’s Descovy to block HIV transmission in men and transgender women, a step toward another PrEP finally coming to market (the sole medicine right now being Gilead’s Truvada). One potential snag — the advisory committee narrowly voted not to recommend the medicine, which is already approved to treat HIV, for women who are not transgender, also referred to as cisgender women.

    August 9, 2019
    Politico
  • An FDA advisory panel overwhelmingly voted 16-2 to recommend Descovy, the fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF), as pre-exposure prophylaxis (PrEP) to reduce HIV acquisition in men who have sex with men (MSM) and transgender women. But murmurs echoed throughout the room as the FDA's Antimicrobial Drugs Advisory Committee split 8-10 on whether to recommend a PrEP indication for F/TAF in cisgender women.

    August 7, 2019
    MedPage Today
  • A flexible vaginal ring loaded with the HIV antiretroviral dapivirine has been hailed as an exciting new HIV prevention option, particularly for women in sub-Saharan Africa who say the insertable vaginal ring is easier to use and more discreet than existing HIV prevention methods.

    August 6, 2019
    The BodyPro
  • A landmark study evaluating HIV risk and hormonal contraception is under fire, with critics arguing the trial was ethically flawed from the start and that its results may limit already narrow birth-control options for African women.

    August 5, 2019
    The BodyPro
  • Funding for HIV prevention research and development is slowing down, according to a new report by the Resource Tracking for HIV Prevention Research and Development Working Group, a collaboration between global HIV organisations – AVAC, IAVI and UNAIDS.

    July 31, 2019
    General
    Independent
  • TB and HIV both are preventable, but cutting the chain of transmission of HIV and TB is proving to be a daunting task. Treatment exists for both TB and HIV but disease-burden and deaths every year are indeed alarming. With countdown on towards TB and AIDS elimination targets for 2030, the writing on the wall is clear: business as usual and 'more of the same' approach is more likely to fail us.

    July 26, 2019
    Modern Ghana
  • The tools needed to end the worldwide AIDS epidemic are either in the hands of clinicians, governments, or patients, or can be implemented by using government and social willpower, researchers said here at the International AIDS Society Conference on HIV Science.

    July 26, 2019
    General
    MedPage Today
  • A whip-thin length of polymer loaded with islatravir, Merck's investigational HIV prevention drug, and implanted into the arm is being investigated as a future option for people who have a hard time taking pills.

    July 24, 2019
    Medscape
  • A "mosaic" vaccine against HIV was well-tolerated and able to produce an immune response against multiple clades, or disease subtypes, in healthy volunteers, a researcher said here.

    July 24, 2019
    MedPage Today
  • In what could eventually become a milestone for HIV prevention, very preliminary tests of an implant containing a new drug suggest that it may protect against infection for a full year. The new implant, by the drug company Merck, was tested in just a dozen subjects for 12 weeks. But experts were quite excited at its potential to revolutionize the long battle against HIV

    July 23, 2019
    New York Times

Pages